Compare Cytokinetics Inc (CYTK) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Honeywell International Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Honeywell International Inc trades at $207 (market cap $65.96B). The key difference: Honeywell International Inc is far larger — about 7.8× Cytokinetics Inc's market cap, and Honeywell International Inc pays a 1.35% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Honeywell International Inc for 90 Days on average.
| CYTK | HON | |
|---|---|---|
Market Cap | $8.50B | $65.96B |
Volume | 2,395,556 | 2,009,898 |
Sector | Health | Industrials |
52-Week High | $87.26 | $248.79 |
52-Week Low | $54.76 | $188.14 |
Typical Hold Time | 19 Days | 90 Days |
Enterprise Value | $8.60B | $90.75B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Honeywell International (HON) trades at $206.6, down 2.95% on the day, with a bearish technical signal despite strong fundamentals including a low P/E of 8 and robust profitability margins. Recent quarterly earnings have consistently beaten expectations, and the company secured a significant $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with a $259.25 price target, representing 25% upside potential from current levels.
The stock presents a compelling value opportunity given its discounted valuation metrics and consistent earnings outperformance, though investors face near-term technical headwinds and execution risks from the company's recent strategic transformation into a pure-play automation business following the spin-off of its aerospace and advanced materials divisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
